
Floseal hemostatic agent reduces blood loss but not transfusion needs in TKA patients

Floseal hemostatic agent reduces blood loss but not transfusion needs in TKA patients
Prospective, Randomized Trial to Evaluate Efficacy of a Thrombin-Based Hemostatic Agent in Total Knee Arthroplasty
J Arthroplasty. 2014 Oct;29(10):1950-5.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
108 patients undergoing unilateral primary total knee arthroplasty were randomly allocated to either receive a thrombin-based topical hemostatic matrix or to a control group who did not receive the hemostatic agent. The study sought to determine the effects of the hemostatic sealant on inblood loss, as well as the need for transfusion. Results revealed the mean blood loss, drain output and length ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Join the Conversation
Please Login or Join to leave comments.